Discontinued — last reported Q2 '21
Current Assets
Restricted Cash
Boston Scientific Restricted Cash decreased by 10.1% to $98.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 40.0%, from $70.00M to $98.00M. Over 4 years (FY 2020 to FY 2024), Restricted Cash shows a downward trend with a -14.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ1 2019
Last reportedQ2 2021
How to read this metric
An increase suggests higher regulatory or contractual obligations, potentially reducing operational liquidity, while a decrease may indicate the release of restricted funds.
Detailed definition
Cash balances that are legally or contractually restricted from being used for general corporate purposes. This often in...
Peer comparison
Standard line item for all major banks; peers disclose this to clarify the portion of cash that is not immediately available for deployment.
Metric ID:
restricted_cashHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $167.00M | $155.00M | $188.00M | $146.00M | $132.00M | $112.00M | $149.00M | $135.00M | $135.00M | $123.00M | $130.00M | $93.00M | $75.00M | $70.00M | $111.00M | $103.00M | $109.00M | $98.00M |
| QoQ Change | — | -7.2% | +21.3% | -22.3% | -9.6% | -15.2% | +33.0% | -9.4% | +0.0% | -8.9% | +5.7% | -28.5% | -19.4% | -6.7% | +58.6% | -7.2% | +5.8% | -10.1% |
| YoY Change | — | — | — | — | -21.0% | -27.7% | -20.7% | -7.5% | +2.3% | +9.8% | -12.8% | -31.1% | -44.4% | -43.1% | -14.6% | +10.8% | +45.3% | +40.0% |
Range$70.00M – $188.00M
CAGR-11.8%
Avg YoY Growth-8.2%
Median YoY Growth-13.7%
Restricted Cash at Other Companies
Frequently Asked Questions
- What is Boston Scientific's restricted cash?
- Boston Scientific (BSX) reported restricted cash of $98.00M in Q3 2025.
- How has Boston Scientific's restricted cash changed year-over-year?
- Boston Scientific's restricted cash increased by 40.0% year-over-year, from $70.00M to $98.00M.
- What is the long-term trend for Boston Scientific's restricted cash?
- Over 4 years (2020 to 2024), Boston Scientific's restricted cash has grown at a -14.5% compound annual growth rate (CAGR), from $208.00M to $111.00M.
- What does restricted cash mean?
- Cash that is set aside for specific purposes and cannot be used for general business needs.